These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37528266)

  • 1. Contribution of constitutional BRCA1 promoter methylation to early-onset and familial breast cancer patients from Pakistan.
    Muhammad N; Azeem A; Bakar MA; Prajzendanc K; Loya A; Jakubowska A; Hamann U; Rashid MU
    Breast Cancer Res Treat; 2023 Nov; 202(2):377-387. PubMed ID: 37528266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutional
    Al-Moghrabi N; Al-Showimi M; Alqahtani A; Almalik O; Alhusaini H; Almalki G; Saad A; Alsunayi E
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer.
    Lønning PE; Nikolaienko O; Pan K; Kurian AW; Eikesdal HP; Pettinger M; Anderson GL; Prentice RL; Chlebowski RT; Knappskog S
    JAMA Oncol; 2022 Nov; 8(11):1579-1587. PubMed ID: 36074460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
    Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U
    BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
    Phuah SY; Looi LM; Hassan N; Rhodes A; Dean S; Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Nov; 14(6):R142. PubMed ID: 23116406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer.
    Prajzendanc K; Domagała P; Hybiak J; Ryś J; Huzarski T; Szwiec M; Tomiczek-Szwiec J; Redelbach W; Sejda A; Gronwald J; Kluz T; Wiśniowski R; Cybulski C; Łukomska A; Białkowska K; Sukiennicki G; Kulczycka K; Narod SA; Wojdacz TK; Lubiński J; Jakubowska A
    Int J Cancer; 2020 Mar; 146(5):1293-1298. PubMed ID: 31469414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoter Hypermethylation and Expression Changes of BRCA1 Gene in a Cohort of Sporadic Breast Cancer Cases among Pakistani Population.
    Arif T; Anwar N
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2395-2401. PubMed ID: 32856871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of FANCM germline variants in BRCA1/2 negative breast and/or ovarian cancer patients from Pakistan.
    Rashid MU; Muhammad N; Shehzad U; Khan FA; Loya A; Hamann U
    Fam Cancer; 2023 Jan; 22(1):31-41. PubMed ID: 35802266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
    Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development.
    Nikolaienko O; Eikesdal HP; Ognedal E; Gilje B; Lundgren S; Blix ES; Espelid H; Geisler J; Geisler S; Janssen EAM; Yndestad S; Minsaas L; Leirvaag B; Lillestøl R; Knappskog S; Lønning PE
    Genome Med; 2023 Dec; 15(1):104. PubMed ID: 38053165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Male breast cancer: No evidence for mosaic BRCA1 promoter methylation involvement.
    Schwartz M; Ibadioune S; Vacher S; Villy MC; Trabelsi-Grati O; Le Gall J; Caputo SM; Delhomelle H; Warcoin M; Moncoutier V; Bourneix C; Boutry-Kryza N; De Pauw A; Stern MH; Buecher B; Mouret-Fourme E; Colas C; Stoppa-Lyonnet D; Masliah-Planchon J; Golmard L; Bieche I
    Breast; 2024 Feb; 73():103620. PubMed ID: 38096711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
    Lenz L; Neff C; Solimeno C; Cogan ES; Abramson VG; Boughey JC; Falkson C; Goetz MP; Ford JM; Gradishar WJ; Jankowitz RC; Kaklamani VG; Marcom PK; Richardson AL; Storniolo AM; Tung NM; Vinayak S; Hodgson DR; Lai Z; Dearden S; Hennessy BT; Mayer EL; Mills GB; Slavin TP; Gutin A; Connolly RM; Telli ML; Stearns V; Lanchbury JS; Timms KM
    Breast Cancer Res Treat; 2023 Nov; 202(1):191-201. PubMed ID: 37589839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
    Tian T; Shan L; Yang W; Zhou X; Shui R
    Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer.
    Wong EM; Southey MC; Fox SB; Brown MA; Dowty JG; Jenkins MA; Giles GG; Hopper JL; Dobrovic A
    Cancer Prev Res (Phila); 2011 Jan; 4(1):23-33. PubMed ID: 20978112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
    Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
    Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines.
    Al-Yousef N; Shinwari Z; Al-Shahrani B; Al-Showimi M; Al-Moghrabi N
    Oncol Rep; 2020 Mar; 43(3):827-838. PubMed ID: 32020216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
    Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
    J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of BRCA1 and BRCA2 genes promoter hypermethylation in breast cancer tissue.
    Lobanova OE; Rossokha ZI; Medvedieva NL; Cheshuk VE; Vereshchako RI; Vershyhora VO; Fishchuk LY; Zakhartseva LM; Gorovenko NG
    Exp Oncol; 2021 Mar; 43(1):56-60. PubMed ID: 33785722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
    Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK;
    BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer.
    Gupta S; Jaworska-Bieniek K; Narod SA; Lubinski J; Wojdacz TK; Jakubowska A
    Breast Cancer Res Treat; 2014 Dec; 148(3):615-22. PubMed ID: 25376744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.